Clinical Trials Logo

Hemorrhagic Fever, Ebola clinical trials

View clinical trials related to Hemorrhagic Fever, Ebola.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06093646 Recruiting - Ebola Virus Disease Clinical Trials

Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda

Ebola+D
Start date: September 22, 2023
Phase: N/A
Study type: Interventional

Screen participants attending 11 healthcare facilities in Mubende District for psychological distress using the locally validated Luganda or English version of the WHO- Self Report Questionnaire (SRQ-20). Those individuals found to have significant psychological distress (a score of 6 and above) will be offered Ebola+D intervention [a stepped care collaborative delivery model to address the medium- to long-term EBOLA associated psychological Distress and psychosocial problems] . A cohort of Ebola Virus Disease (EVD) affected individuals accessing the Ebola +D mental health intervention will be recruited and followed up for 12 months with assessments at three time points; baseline, 3 months and 12 months.

NCT ID: NCT05494801 Recruiting - Ebola Virus Disease Clinical Trials

Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III

Start date: August 25, 2022
Phase:
Study type: Observational

Background: Ebola virus disease (EVD) is a viral fever that can cause internal bleeding. The death rate from EVD is very high. In a 2014 outbreak in West Africa, 28,000 were affected and 11,000 died. EVD may also affect the brain and nervous system, but this is not well studied. People with EVD report headaches and mental status changes. Some rarely had strokes and seizures. Neurological issues can continue for years after people recover from the initial EVD infection. Objective: This is a natural history study to learn more about how EVD continues to affect survivors brain and nervous system after 5 years. Eligibility: People aged 18 years or older who participated in the PREVAIL III Neurology Substudy. Participants can be either an EVD survivor or a close contact. Close contacts are people who had a relationship with a survivor of EVD. Design: Participants will have 1 clinic visit. They will have a physical exam. Their vital signs will be measured. They will also have a neurological checkup. The exam will assess their mental status. Their senses, reflexes, and coordination will be tested. They will be observed while walking to assess their gait. This exam will take about 1 hour. Participants will have an interview. They will answer questions about any symptoms they have that may be affecting the brain or nervous system. This will take about 1 hour. No other procedures will be performed during this visit.

NCT ID: NCT04717830 Recruiting - Ebola Virus Disease Clinical Trials

An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease

Start date: February 15, 2021
Phase: Phase 1
Study type: Interventional

Open-label safety, tolerability, pharmacokinetics and immunogenicity study in three dose escalation groups

NCT ID: NCT02967003 Recruiting - Clinical trials for Hemorrhagic Fever, Ebola

Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Start date: May 2016
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the long-term safety profile of Ad26.ZEBOV and MVA-BN-Filo in participants previously exposed to these vaccines in Phase 1, 2, or 3 clinical studies.

NCT ID: NCT02333578 Recruiting - Ebola Virus Disease Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment

EVD001
Start date: November 2014
Phase: N/A
Study type: Interventional

A Phase I/II Pilot Clinical Trial to Evaluate the Efficacy and Safety of Ebola Virus Disease (EVD) Convalescent Plasma (ECP) for treatment of EVD.